Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a staphylococcus aureus dermonecrosis model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 299-308

  Hilliard, Jamese J ^a   Datta, Vivekana ^a   Tkaczyk, Christine ^a   Hamilton, Melissa ^a   Sadowska, Agnieszka ^a   Jones Nelson, Omari ^a   O'Day, Terrence ^a   Weiss, William J ^b   Szarka, Szabolcs ^b   Nguyen, Vien ^b   Prokai, Laszlo ^b   Suzich, JoAnn ^a   Stover, C Kendall ^a   Sellmana, Bret R ^a  

^a Department of Infectious Diseasea ^*  (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; MONOCLONAL ANTIBODY; STAPHYLOCOCCUS ALPHA TOXIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; HEMOLYSIN; NEUTRALIZING ANTIBODY; STAPHYLOCOCCAL ALPHA-TOXIN; SUVRATOXUMAB;

ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NEUTROPHIL; NONHUMAN; SKIN INFECTION; SKIN NECROSIS; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TISSUE INJURY; WOUND HEALING; ANIMAL; BAGG ALBINO MOUSE; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; MICROBIOLOGY; NECROSIS; PATHOGENICITY; PATHOLOGY; STAPHYLOCOCCAL SKIN INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HEMOLYSIN PROTEINS; LINEZOLID; MICE, INBRED BALB C; NECROSIS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84920171745     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03918-14     Document Type: Article

References (45)

1. Mera RM, Suaya JA, Amrine-Madsen H, Hogea CS, Miller LA, Lu EP, Sahm DF, O'Hara P, Acosta CJ. 2011. Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion. Microb Drug Resist 17:321-328. http://dx.doi.org/10.1089 /mdr.2010.0193.
2. Ray GT, Suaya JA, Baxter R. 2013. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. Population: a retrospective population-based study. BMC Infect Dis 13:252. http://dx .doi.org/10.1186/1471-2334-13-252.
3. Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM. 2012. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureuscomplicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. Clin Ther 34:1667-1673. http://dx .doi.org/10.1016/j.clinthera.2012.06.018.
4. Labreche MJ, Lee GC, Attridge RT, Mortensen EM, Koeller J, Du LC, Nyren NR, Trevino LB, Trevino SB, Pena J, Mann MW, Munoz A, Marcos Y, Rocha G, Koretsky S, Esparza S, Finnie M, Dallas SD, Parchman ML, Frei CR. 2013. Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med 26:508-517. http://dx.doi.org /10.3122/jabfm.2013.05.120247.
5. Hilliard JJ, Fernandez J, Melton J, Macielag MJ, Goldschmidt R, Bush K, Abbanat D. 2009. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob Agents Chemother 53:2028-2033. http://dx.doi.org/10.1128/AAC.00833-08.
6. Long KS, Vester B. 2012. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 56: 603-612. http://dx.doi.org/10.1128/AAC.05702-11.
7. Campanile F, Mongelli G, Bongiorno D, Adembri C, Ballardini M, Falcone M, Menichetti F, Repetto A, Sabia C, Sartor A, Scarparo C, Tascini C, Venditti M, Zoppi F, Stefani S. 2013. Worrisome trend of new multiple mechanisms of linezolid resistance in staphylococcal clones diffused in Italy. J Clin Microbiol 51:1256-1259. http://dx.doi.org/10.1128 /JCM.00098-13.
8. Miller LS, Cho JS. 2011. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 11:505-518. http://dx.doi.org/10 .1038/nri3010.
9. Tkaczyk C, Hamilton MM, Datta V, Yang XP, Hilliard JJ, Stephens GL, Sadowska A, Hua L, O'Day T, Suzich J, Stover CK, Sellman BR. 2013. Alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLoS One 8:e75103. http://dx.doi.org/10 .1371/journal.pone.0075103.
10. Abtin A, Jain R, Mitchell AJ, Roediger B, Brzoska AJ, Tikoo S, Cheng Q, Ng LG, Cavanagh LL, von Andrian UH, Hickey MJ, Firth N, Weninger W. 2014. Perivascular macrophages mediate neutrophil recruitment during bacterial skin infection. Nat Immunol 15:45-53. http: //dx.doi.org/10.1038/ni.2769.
11. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. 2013. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 56:1554-1561. http://dx.doi.org/10 .1093/cid/cit123.
12. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF. 10 September 2014. Mechanisms of neutralization of a human anti-alpha toxin antibody. J Biol Chem http://dx.doi.org/10.1074/jbc.M114.601328.
13. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O'Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR. 2014. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58:1108-1117. http://dx.doi.org/10.1128/AAC.02190-13.
14. Dall'Acqua WF, Kiener PA, Wu H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524. http://dx.doi.org/10.1074/jbc.M604292200.
15. Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. 2013. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 57:6147-6153. http://dx.doi.org /10.1128/AAC.01285-13.
16. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. 2002. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171-5180. http://dx.doi.org/10.4049/jimmunol .169.9.5171.
17. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A8. Approved standard, 8th ed. CLSI, Wayne, PA.
18. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR. 2012. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 19:377-385. http: //dx.doi.org/10.1128/CVI.05589-11.
19. Stein GE, Throckmorton JK, Scharmen AE, Weiss WJ, Prokai L, Smith CL, Havlichek DH. 2013. Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. J Antimicrob Chemother 68:2852-2858. http://dx.doi.org/10.1093/jac/dkt267.
20. Estes KS, Derendorf H. 2010. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res 15:533-543. http://dx.doi.org/10.1186/2047-783X-15-12-533.
21. Sampedro GR, DeDent AC, Becker RE, Berube BJ, Gebhardt MJ, Cao H, Bubeck Wardenburg J. 16 April 2014. Targeting Staphylococcus aureus alpha-toxin as a novel approach to reduce severity of recurrent skin and soft-tissue infections. J Infect Dis http://dx.doi.org/10 .1093/infdis/jiu223.
22. Inoshima, N, Wang Y, Bubeck Wardenburg J. 2012. Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J Investig Dermatol 132: 1513-1516. http://dx.doi.org/10.1038/jid.2011 .462.
23. Montgomery CP, Daniels MD, Zhao F, Spellberg B, Chong AS, Daum RS. 2013. Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PLoS One 8:e69508. http://dx.doi.org/10.1371 /journal.pone.0069508.
24. Becker RE, Berube BJ, Sampedro GR, Dedent AC, Bubeck Wardenburg J. 2014. Tissue-specific patterning of host innate immune responses by Staphylococcus aureus alpha-toxin. J Innate Immun http://dx.doi.org/10 .1159/000360006.
25. Kim MH, Granick JL, Kwok C, Walker NJ, Borjesson DL, Curry FR, Miller LS, Simon SI. 2011. Neutrophil survival and c-kit(-)-progenitor proliferation in Staphylococcus aureus-infected skin wounds promote resolution. Blood 117:3343-3352. http://dx.doi.org/10.1182/blood-2010 -07-296970.
26. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, Magorien JE, Blauvelt A, Kolls JK, Cheung AL, Cheng G, Modlin RL, Miller LS. 2010. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 120:1762-1773. http://dx.doi.org/10.1172/JCI40891.
27. Mahdavian Delavary B, van der Veer WM, van Egmond M, Niessen FB, Beelen RH. 2011. Macrophages in skin injury and repair. Immunobiology 216:753-762. http://dx.doi.org/10.1016/j.imbio.2011.01.001.
28. Cho JS, Guo Y, Ramos RI, Hebroni F, Plaisier SB, Xuan C, Granick JL, Matsushima H, Takashima A, Iwakura Y, Cheung AL, Cheng G, Lee DJ, Simon SI, Miller LS. 2012. Neutrophil-derived IL-1beta is sufficient for abscess formation in immunity against Staphylococcus aureus in mice. PLoS Pathog 8:e1003047. http://dx.doi.org/10.1371/journal.ppat.1003047.
29. Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Muller W, Roers A, Eming SA. 2010. Differential roles of macrophages in diverse phases of skin repair. J Immunol 184:3964-3977. http://dx.doi.org/10.4049/jimmunol.0903356.
30. Dryden MS. 2010. Complicated skin and soft tissue infection. J Antimicrob Chemother 65(Suppl 3):35-44. http://dx.doi.org/10.1093/jac/dkq302.
31. Dryden MS. 2014. Developments in skin and soft tissue infection. Curr Opin Infect Dis 27:115. http://dx.doi.org/10.1097/QCO.0000000000000051.
32. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. 2002. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481-1490. http://dx .doi.org/10.1086/340353.
33. Kobayashi SD, Musser JM, DeLeo FR. 2012. Genomic analysis of the emergence of vancomycin-resistant Staphylococcus aureus. mBio 3(4): e00170-12. http://dx.doi.org/10.1128/mBio.00170-12.
34. Locke JB, Rahawi S, Lamarre J, Mankin AS, Shaw KJ. 2012. Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05. Antimicrob Agents Chemother 56:332-340. http://dx.doi .org/10.1128/AAC.05420-11.
35. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alphahemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202:1050-1058. http://dx.doi.org/10.1086/656043.
36. Kernodle DS, Voladri RK, Menzies BE, Hager CC, Edwards KM. 1997. Expression of an antisense hla fragment in Staphylococcus aureus reduces alpha-toxin production in vitro and attenuates lethal activity in a murine model. Infect Immun 65:179-184.
37. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205:287-294. http://dx.doi .org/10.1084/jem.20072208.
38. Berube BJ, Bubeck Wardenburg J. 2013. Staphylococcus aureus alphatoxin: nearly a century of intrigue. Toxins (Basel) 5:1140-1166. http://dx .doi.org/10.3390/toxins5061140.
39. Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP. 2012. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother 56:2342-2346. http://dx.doi.org/10.1128/AAC.06427-11.
40. Sakoulas G, Eliopoulos GM, Fowler VG, Jr, Moellering RC, Jr, Novick RP, Lucindo N, Yeaman MR, Bayer AS. 2005. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 49:2687-2692. http://dx .doi.org/10.1128/AAC.49.7.2687-2692.2005.
41. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF. 2013. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis 208:75-82. http://dx.doi .org/10.1093/infdis/jit129.
42. Molne L, Verdrengh M, Tarkowski A. 2000. Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect Immun 68:6162-6167.
43. Koh TJ, DiPietro LA. 2011. Inflammation and wound healing: the role of the macrophage. Expert Rev Mol Med 13:e23. http://dx.doi.org/10.1017 /S1462399411001943.
44. Martin P, Leibovich SJ. 2005. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 15:599-607. http://dx.doi .org/10.1016/j.tcb.2005.09.002.
45. Sharma-Kuinkel BK, Wu Y, Tabor DE, Mok H, Sellman BR, Jenkins A, Yu L, Jafri HS, Rude TH, Ruffin F, Schell WA, Park LP, Yan Q, Thaden JT, Messina JA, Fowler VG, Jr, Esser MT. 12 November 2014. Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia. J Clin Microbiol http://dx .doi.org/10.1128/JCM.02023-14.